ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Knight Therapeutics Inc

Knight Therapeutics Inc (GUD)

5.55
0.00
(0.00%)
Closed August 07 4:12PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
5.55
Bid
5.50
Ask
5.55
Volume
75,025
5.43 Day's Range 5.59
4.35 52 Week Range 6.22
Market Cap
Previous Close
5.55
Open
5.45
Last Trade
28
@
5.55
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
54,516
Shares Outstanding
101,170,000
Dividend Yield
-
PE Ratio
-33.29
Earnings Per Share (EPS)
-0.17
Revenue
331.1M
Net Profit
-16.84M

About Knight Therapeutics Inc

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Montreal, Quebec, Can
Founded
1970
Knight Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the Toronto Stock Exchange with ticker GUD. The last closing price for Knight Therapeutics was $5.55. Over the last year, Knight Therapeutics shares have traded in a share price range of $ 4.35 to $ 6.22.

Knight Therapeutics currently has 101,170,000 shares outstanding. The market capitalization of Knight Therapeutics is $561.49 million. Knight Therapeutics has a price to earnings ratio (PE ratio) of -33.29.

GUD Latest News

Notice of Knight Therapeutics' Second Quarter 2024 Results Conference Call

MONTREAL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2024...

Knight Announces Normal Course Issuer Bid

MONTREAL, July 11, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "),  a leading pan-American (ex-US) specialty pharmaceutical company, announced today...

Knight Therapeutics Reports First Quarter 2024 Results

MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported...

Knight Therapeutics Inc. announces voting results from the Annual General Meeting

MONTREAL, May 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the...

Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City

MONTREAL, May 07, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:  GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia...

Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call

MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024...

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia...

Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity

MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2024 Report on...

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.07-1.245551601425.625.85.43547025.59937291CS
4-0.1-1.769911504425.655.885.43483255.67075424CS
12-0.5-8.264462809926.056.225.38545165.76997869CS
260.132.398523985245.426.225.21626995.63906339CS
520.7615.8663883094.796.224.35632525.30448039CS
1560.47.766990291265.156.224.281393725.27783195CS
260-1.97-26.19680851067.528.884.282172515.90883865CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VPHValeo Pharma Inc
$ 0.095
(35.71%)
3k
BNGBengal Energy Ltd
$ 0.025
(25.00%)
46.1k
ANRGAnaergia Inc
$ 0.54
(24.14%)
182.95k
XAMXanadu Mines Ltd
$ 0.06
(20.00%)
189.92k
RBYRubellite Energy Inc
$ 2.28
(10.14%)
134.25k
PBLPollard Banknote Ltd
$ 18.22
(-35.66%)
118.11k
TIXTTelus International CDA Inc
$ 4.17
(-27.48%)
2.3M
PPRPrairie Provident Resources Inc
$ 0.03
(-25.00%)
426.72k
SBNS Split Corp
$ 1.76
(-19.63%)
3.04k
BKIBlack Iron Inc
$ 0.045
(-18.18%)
190.61k
ENBEnbridge Inc
$ 52.76
(0.29%)
19.09M
SUSuncor Energy Inc
$ 50.98
(0.10%)
14.38M
TOUTourmaline Oil Corp
$ 56.68
(-0.39%)
13.52M
TDToronto Dominion Bank
$ 77.31
(-1.70%)
11.79M
MFCManulife Financial Corporation
$ 33.96
(-0.96%)
10.51M

GUD Discussion

View Posts
sumotrader sumotrader 9 years ago
Loaded 1600 more shares today. GUD is about to take off.
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
This must be some sort of record,.. " the Company reported revenues of $109,608 and net income of $124,981,439."

http://www.gud-knight.com/en/knight-reports-fourth-quarter-and-year-ended-december-31-2014-results
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
Knight Therapeutics GUD.TO : Mackie Research starts with buy rating; target price of C$12

http://www.investorvillage.com/groups.asp?mb=6781&mn=83648&pt=msg&mid=14732670
👍️0
OneStepAhead OneStepAhead 9 years ago
On a tear
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
GOD is GUD. :)
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
KHTRF is the OTC Ticker for Americans
or
GUD on the TSX for Canadians


LONG on this one.
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
GUD is flying along nicely,.. Paladin II is in GUD hands, Goodman building another BEAST!
👍️0
OneStepAhead OneStepAhead 10 years ago
GUD Knight Therapeutics

Knight Therapeutics Inc. ("Knight" or the "Company") (TSX:GUD) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by GMP Securities L.P. and including Cormark Securities Inc., National Bank Financial Inc., Laurentian Bank Securities Inc., Bloom Burton & Co., Clarus Securities Inc., Mackie Research Capital Corporation and TD Securities Inc. (the "Underwriters"), pursuant to which the Underwriters have agreed to purchase 11,111,120 common shares of the Company (the "Common Shares") at a price of $6.75 per Common Share for gross proceeds to Knight of $75,000,060 (the "Offering"). In addition, the Underwriters will have the option, exercisable for a period of 30 days after the closing date, to acquire up to an aggregate of 1,666,668 additional Common Shares ($11,250,009) at the offering price to cover over-allotments, if any (the "Over-Allotment Option"). If the Over-Allotment Option is exercised in full, the total gross proceeds of the Offering shall be $86,250,069.

http://www.marketwired.com/press-release/knight-therapeutics-enters-into-agreement-75-million-bought-deal-common-shares-tsx-gud-1973898.htm
👍️0
OneStepAhead OneStepAhead 10 years ago
GUD Knight Therapeutics

After selling off his specialty pharmaceutical company Paladin Labs Inc. in a deal worth $3-billion, Montreal entrepreneur Jonathan Goodman is starting from scratch with a new drug distribution venture.

http://www.theglobeandmail.com/globe-investor/investment-ideas/a-fresh-stock-with-a-veteran-face/article17189152/
👍️0
Greedy G Greedy G 10 years ago
TNEN:

http://stockcharts.com/h-sc/ui?s=TNEN&p=D&b=5&g=0&id=p74917584188
👍️0

Your Recent History

Delayed Upgrade Clock